Prof. Ling Xi 奚玲
Chief Physician, Professor
Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Gynecologic tumors and endometriosis, with a focus on laparoscopic minimally invasive surgery.
Dr. Xi is a Chief Physician and Professor at Tongji Hospital. With nearly 30 years of experience, Dr. Xi performs approximately 600 surgeries annually. Research interests include the etiology of cervical cancer and targeted therapy for micrometastases in gynecologic tumors.
Name order: in Chinese the family name comes first (Xi Ling). Papers usually list the name as Ling Xi or Xi L.
Selected publications
92 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Oncol (Dordr), 2026 (senior author): Cucurbitacin I induces pyroptosis via NF-κB/TNFR1/caspase-8/caspase-3/GSDME axis for cervical cancer treatment. PubMed 42980946
- EJNMMI Res, 2026 (senior author): Enhanced in-vivo persistence and PET imaging performance of [(68)Ga]Ga-DOTA-TMVP1446/GS5 as a VEGFR-3 radiotracer. PubMed 41933210
- Phytomedicine, 2026 (senior author): Cucurbitacin I induces immunogenic cell death and synergistically potentiates cisplatin efficacy in epithelial ovarian cancer. PubMed 41380410
- Cell Death Dis, 2025 (senior author): Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. PubMed 41315319
- Mater Today Bio, 2025 (senior author): TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy. PubMed 40487160
- Theranostics, 2025 (senior author): TMTP1-modified nanocarrier boosts cervical cancer immunotherapy by eliciting pyroptosis. PubMed 40303327
- Oncol Lett, 2025 (senior author): SNS‑032 combined with decitabine induces caspase‑3/gasdermin E‑dependent pyroptosis in breast cancer cells. PubMed 40070781
- Biochem Pharmacol, 2025 (senior author): Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells. PubMed 39643123
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion